GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors
- First Posted Date
- 2007-08-15
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 30
- Registration Number
- NCT00516672
- Locations
- 🇯🇵
GSK Investigational Site, Saitama, Japan
Endotoxin Challenge Study For Healthy Men and Women
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-08-13
- Last Posted Date
- 2017-08-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 37
- Registration Number
- NCT00515268
- Locations
- 🇩🇪
GSK Investigational Site, Hannover, Niedersachsen, Germany
Safety Study Using GSK573719 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2007-08-13
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 24
- Registration Number
- NCT00515502
- Locations
- 🇩🇪
GSK Investigational Site, Hamburg, Germany
Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects
- Conditions
- Infections, MeningococcalMeningococcal Vaccines
- Interventions
- Biological: MencevaxBiological: Nimenrix
- First Posted Date
- 2007-08-10
- Last Posted Date
- 2020-10-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1504
- Registration Number
- NCT00514904
- Locations
- 🇸🇦
GSK Investigational Site, Riyadh, Saudi Arabia
A Post-marketing Safety Study of GSK Bio IPV Vaccine (PoliorixTM) in Korean Children
- Conditions
- Poliomyelitis
- Interventions
- Biological: Poliomyelitis vaccine (inactivated) -PoliorixTM
- First Posted Date
- 2007-08-09
- Last Posted Date
- 2012-03-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 349
- Registration Number
- NCT00514033
- Locations
- 🇰🇷
GSK Investigational Site, Seoul, Korea, Republic of
A Study To Investigate Effects Of GSK561679 On Brain Activation During Emotional Processing In Healthy Volunteers
- Conditions
- Depressive Disorder and Anxiety Disorders
- Interventions
- Drug: single dose
- First Posted Date
- 2007-08-08
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 22
- Registration Number
- NCT00513565
- Locations
- 🇺🇸
GSK Investigational Site, La Jolla, California, United States
To Investigate If Single Doses Of GSK618334 Are Safe And To Investigate Blood Levels Of GSK618334
- Conditions
- Substance Dependence
- Interventions
- Drug: GSK618334 matching placebo tablets
- First Posted Date
- 2007-08-08
- Last Posted Date
- 2017-09-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20
- Registration Number
- NCT00513279
- Locations
- 🇬🇧
GSK Investigational Site, Harrow, Middlesex, United Kingdom
A Phase I Study to Test Alternate Oral Formulations vs the Current Tablet Formulation of Lapatinib
- Conditions
- Healthy Subjects
- First Posted Date
- 2007-08-08
- Last Posted Date
- 2015-02-16
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00513253
- Locations
- 🇺🇸
GSK Investigational Site, Buffalo, New York, United States
Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given as Booster or a 2 Dose Catch up Schedule
- Conditions
- Infections, Streptococcal
- Interventions
- Biological: SynflorixBiological: Infanrix HexaBiological: Havrix
- First Posted Date
- 2007-08-08
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 163
- Registration Number
- NCT00513409
- Locations
- 🇨🇱
GSK Investigational Site, Santiago, Región Metro De Santiago, Chile
A Study In Patients With Irritable Bowel Syndrome To Measure Hormone Response After Dosing With GW876008 And Gsk561679
- Conditions
- Irritable Bowel Syndrome
- Interventions
- Drug: GW876008 and GSK561679
- First Posted Date
- 2007-08-06
- Last Posted Date
- 2015-03-02
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00511563